Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial

Lung Cancer

Volumn 58, Issue 2, 2007, Pages 238-245

  Pallares C ^a   Capdevila, J ^a   Paredes, A ^b   Farre N ^a   Ciria, J P ^b   Membrive, I ^a   Basterrechea, L ^b   Gomez Segura, G ^a   Barnadas, A ^a  

^a HOSPITAL SANT PAU   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Carboplatin; Concurrent chemoradiotherapy; Non small cell lung cancer; Paclitaxel; Stage IIIB

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION PNEUMONIA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG TOXICITY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT COMPLIANCE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 34848864621     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.003     Document Type: Article

References (24)

1. Glassberg A.B., and Cornett P. Lung. Non-small-cell. In: Dollinger M., Rosenbaum E.H., and Cable G. (Eds). Everyone's guide to cancer therapy (1994), Somerville House Books Limited, Kansas City, MO 469-475
2. Perez C.A., Bauer M., Emami B.N., Byhardt R., Brady L.W., Doggett R.L., et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12 (1986) 539-547
3. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
4. Sause W., Sacott C., and Taylor S. Preliminary results of a phase III trial in regional advanced non-respectable non-small-cell lung cancer: Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. J Natl Cancer Inst 87 (1995) 198-205
5. Le Chevalier T., Arriagada R., and Quoix E. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non small cell lung cancer. Lung Cancer 10 (1944) 5239-5244
6. Schaske-Koning C., Van der Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 8 (1992) 524-530
7. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 22 (2003) [abstract 2499]
8. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
9. Fournel P., Robinet G., Thomas P., Souquet P.J., Léna H., Vergnenégre A., et al. Randomized phase III trial of sequencial chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 25 (2005) 5910-5917
10. Choy H., Devore R.F., Hande K.R., Porter L.L., Rosenblatt P., Yunus F., et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47 (2000) 931-937
11. Choy H., Akeley W., Safran H., Graziano S., Chung C., Williams T., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16 (1998) 3316-3322
12. Belani C.P., Aisner J., Day R., Ramanathan R., Jett J., Capozzoli M.J., et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16 (1997) 448a [Abstract 1608]
13. Langer C.J., Movsas B., Hudes R., Schol J., Keenan E., Kilpatrick D., et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol 24 Suppl. 12 (1997) S12-89-S12-95
14. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
15. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York p. 167-177
16. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
17. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara P.N., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
18. Kim Y.S., Yoon S.M., Choi E.K., Yi B.Y., Kim J.H., Ahn S.D., et al. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 76-81
19. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiation for satge IIIB non-small-cell lung cancer: cancer and leukemia group study 9431. J Clin Oncol 20 (2002) 4191-4198
20. Fournel P., Vergnenégre A., Robinet G., Léna H., Gervais R., Le Caer H., et al. Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): randomized phase II trial GFPC-GLOT-IFCT 02-01. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 7048]
21. Lau D., Leigh B., Gandara D., Edelman M., Morgan R., Israel V., et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California cancer consortium phase II. J Clin Oncol 19 (2001) 442-447
22. Jeremic B., Milicic B., Acimovic L., and Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol 23 (2005) 1144-1151
23. Saunders M., Dische S., Barret A., Harvey A., Griffiths G., and Parmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: mature data from the randomized multicenter trial. Radiother Oncol 52 (1999) 137-148
24. Belani C.P., Wang W., Johnson D.H., Wagner H., Schiller J., Veeder M., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767